Roswell Park researchers are making waves at the 2026 AACR meeting in San Diego, presenting groundbreaking work on aggressive cancers. Their findings offer new hope for patients, particularly in triple-negative breast cancer and metastatic colorectal cancer. Here's a breakdown of their latest discoveries and the impact they could have:
Targeted Therapy vs. Standard Chemo in HER2-Amplified Metastatic Colorectal Cancer
Roswell Park investigators led a retrospective study comparing targeted therapy (trastuzumab deruxtecan) to standard chemotherapy in HER2-positive, microsatellite-stable metastatic colorectal cancer. The results are promising, showing that targeted therapy enhances five-year overall survival. This is significant because current treatments often fail due to various patient factors like general functioning and prior treatments. By filling this knowledge gap, the study paves the way for more effective treatment strategies.
Why it matters: This research could lead to personalized treatment plans, improving outcomes for patients with this aggressive cancer subtype.
What's fascinating: The study highlights the importance of considering individual patient characteristics in treatment decisions, moving away from a one-size-fits-all approach.
Novel Therapy Targets DNA Damage Response in p53-Mutant Cancers
Roswell Park researchers developed a triple-drug regimen targeting p53-mutant cancers, which are often associated with poor outcomes. The regimen combines trifluridine/tipiracil (TAS102/Lonsurf) with talazoparib (Talzenna) and a G2-checkpoint kinase inhibitor. In preclinical studies, this combination achieved strong tumor suppression without detectable toxicity.
Why it matters: This approach could revolutionize treatment for p53-mutant cancers, offering a promising new strategy for patients with limited treatment options.
What's fascinating: The use of multiple drugs with different mechanisms of action demonstrates the complexity of cancer biology and the potential for combination therapies to overcome resistance.
Promising Combination Therapy for Metastatic Triple-Negative Breast Cancer
Gokul Das and colleagues presented preclinical research on a novel combination therapy targeting metastatic triple-negative breast cancer. This aggressive subtype is challenging to treat, but their findings suggest a promising new direction.
Why it matters: This research could lead to more effective treatments for triple-negative breast cancer, improving survival rates and quality of life for patients.
What's fascinating: The discovery of drug synergy and its impact on tumor biology highlights the potential for precision medicine in cancer treatment.
Roswell Park's presentations at the AACR meeting showcase their commitment to innovation and patient-centered care. By translating these findings into clinical practice, they have the potential to significantly improve outcomes for patients with aggressive cancers.
